Driving Antibody Discovery With Synthetic Biology

This content is brought to you by Integrated DNA Technologies, a Danaher Operating Company.

Advances in synthetic biology are reshaping how antibody therapeutics are discovered, accelerating timelines while expanding what’s scientifically possible. High-throughput DNA synthesis enables rapid construction of diverse antibody libraries, helping researchers overcome traditional screening bottlenecks and evaluate thousands of variants in parallel. Techniques such as phage display, paired with scalable gene fragment synthesis, support efficient hit generation and lead optimization across increasingly complex antibody formats. The growing role of AI and machine learning further enhances this process, guiding library design, predicting antibody performance, and streamlining candidate selection. Together, these innovations are enabling more precise engineering of antibodies with improved affinity, stability, and developability.

Explore how these capabilities can elevate your antibody discovery workflows.